Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02021500 · ClinicalTrials.gov registry record
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
A clinical trial of Pancreatic Cancer, sponsored by Celgene.
- Completed
- Registry status
- 40
- Enrollment target
- 20
- Study locations
NCT02021500 is a study of Pancreatic Cancer that has completed, run by Celgene. The registered enrollment target is 40 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT02021500, a study of Pancreatic Cancer, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
Conditions Studied
Interventions
- DRUG ABI-007
Study Locations (20)
Arizona
- TGen Clinical Research Services - Scottsdale
- Mayo Clinic - Scottsdale
Florida
- Florida Cancer Specialists - Englewood
- Florida Cancer Specialist - Tavares
Virginia
- Fairfax-Northern Virginia Haematology-Oncology - Fairfax
- Virginia Cancer Institute - Richmond
New South Wales
- Macarthur Cancer Therapy Centre - Campbelltown
- Prince of Wales Hospital - Randwick
California
- Pacific Shores Medical Group - Long Beach
Colorado
- University of Colorado Cancer Center - Aurora
Indiana
- Indiana University - Indianapolis
Massachusetts
- University of Massachusetts Memorial Medical Center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-01-02 |
| Est. Completion | 2015-04-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02021500
The ClinicalTrials.gov registry entry for NCT02021500 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which ABI-007 is the first listed.
NCT02021500 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Arizona, Florida, Virginia.
Frequently Asked Questions
What is clinical trial NCT02021500 about?
NCT02021500 is a clinical study titled "A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.". A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
What is the current status of trial NCT02021500?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2014-01-02. Estimated completion is 2015-04-16.
What conditions does trial NCT02021500 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT02021500?
The interventions under investigation include: ABI-007 (DRUG).
Who is sponsoring clinical trial NCT02021500?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02021500 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.